文献速递前列腺癌

皮下脂肪分布是去势抵抗性前列腺癌患者的预后生物标志物

Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer.
PubMed 文献 · J Urol · 2018-01-31

这项多中心回顾性研究纳入282例去势抵抗性前列腺癌(CRPC)患者,通过CT测定皮下脂肪指数、内脏脂肪指数和骨骼肌指数。结果显示皮下脂肪指数≥39.9 cm²/m²的患者1年无进展生存和2年癌症特异性生存优于<39.9 cm²/m²的患者(p=0.009和0.021)。

要点

  • CRPC诊断时皮下脂肪指数<39.9 cm²/m²是癌症特异性生存的独立预测因子。
  • 皮下脂肪指数≥39.9 cm²/m²的患者接受更多多西他赛周期,1年无进展生存和2年癌症特异性生存更优。
  • CT测定的皮下脂肪指数可作为客观预后因素用于讨论治疗选择。

核心结论

  • CRPC诊断时皮下脂肪指数≥39.9 cm²/m²的患者无进展生存率和癌症特异性生存率高于<39.9 cm²/m²的患者。
  • CT测定的皮下脂肪指数可作为有用的客观预后因素来讨论患者治疗选择。
  • 需要进一步研究以确定每种身体成分参数在药代动力学和肿瘤学结局中的作用。

研究设计与样本

  • 多中心回顾性研究,纳入2009年9月至2017年3月间诊断的282例连续去势抵抗性前列腺癌患者。
  • 通过计算机断层扫描(CT)数据测定CRPC诊断时的皮下脂肪指数、内脏脂肪指数和骨骼肌指数。
  • 生存分析分别以皮下脂肪指数39.9 cm²/m²、内脏脂肪指数58 cm²/m²和骨骼肌指数52.4 cm²/m²为截断值进行二分。

主要发现

  • CRPC诊断时,癌症特异性生存的独立预测因素包括前列腺特异性抗原水平、Gleason评分≥8、体能状态、从雄激素剥夺治疗至CRPC的较短间隔以及皮下脂肪指数<39.9 cm²/m²。
  • 中位随访16.0个月期间,皮下脂肪指数≥39.9 cm²/m²的患者接受的多西他赛周期数多于<39.9 cm²/m²的患者。
  • 与皮下脂肪指数<39.9 cm²/m²的患者相比,≥39.9 cm²/m²的患者1年无进展生存和2年癌症特异性生存更优(p=0.009和0.021)。

关键数值与推荐

  • 皮下脂肪指数截断值为39.9 cm²/m²。
  • 内脏脂肪指数截断值为58 cm²/m²。
  • 骨骼肌指数截断值为52.4 cm²/m²。
  • 皮下脂肪指数≥39.9 cm²/m²组 vs <39.9 cm²/m²组:1年无进展生存和2年癌症特异性生存更优(p=0.009和0.021)。

临床怎么用

  • CRPC诊断时可通过CT测定的皮下脂肪指数进行预后分层。
  • 皮下脂肪指数≥39.9 cm²/m²的患者可能接受更多多西他赛周期。
  • 皮下脂肪指数可作为客观预后因素用于讨论患者治疗选择。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The relationship between body fat distribution and survival remains unclear in patients with castration resistant prostate cancer treated with docetaxel and androgen receptor axis targeted agents. We investigated whether body composition parameters could predict radiographic progression-free and cancer specific survival in patients with castration resistant prostate cancer. MATERIALS AND METHODS: In this multicenter retrospective study we evaluated data on 282 consecutive patients diagnosed with castration resistant prostate cancer between September 2009 and March 2017. The subcutaneous fat index, the visceral fat index and the skeletal muscle index at the diagnosis of castration resistant prostate cancer were determined by computerized tomography data. Survival analyses were performed using the subcutaneous fat, visceral fat and skeletal muscle indexes dichotomized at 39.9, 58 and 52.4 cm2/m2, respectively. RESULTS: At the diagnosis of castration resistant prostate cancer, cancer specific survival was independently predicted using prostate specific antigen levels, Gleason score 8 or greater, performance status, a shorter interval from androgen deprivation therapy to castration resistant prostate cancer and a subcutaneous fat index of less than 39.9 cm2/m2. During the median followup of 16.0 months patients with a subcutaneous fat index of 39.9 cm2/m2 or greater received more docetaxel cycles than patients with a subcutaneous fat index of less than 39.9 cm2/m2. Compared to patients with a subcutaneous fat index of less than 39.9 cm2/m2 those with an index of 39.9 cm2/m2 or greater had better 1-year progression-free and 2-year cancer specific survival (p = 0.009 and 0.021, respectively). CONCLUSIONS: Patients with a subcutaneous fat index of 39.9 cm2/m2 or greater at the diagnosis of castration resistant prostate cancer showed higher progression-free and cancer specific survival rates than those with a subcutaneous fat index of less 39.9 cm2/m2 at diagnosis. The subcutaneous fat index determined by computerized tomography data could serve as a useful objective prognostic factor to discuss patient therapeutic options. Further studies are needed to define the roles of each body composition parameter in relation to pharmacokinetics and oncologic outcome.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lee JS, Lee HS, Ha JS, et al. Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer. J Urol. 2018. PMID: 29366641. doi:10.1016/j.juro.2018.01.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。